Insights on Clinical Trials
-
Driving Down COGS: Leveraging Automation Technologies And Mitigating Risk
11/17/2023
The technologies aimed at automating and standardizing cell therapy production are poised to offer advanced therapy companies and CDMOs process-level improvements that streamline and accelerate workflows.
-
The Eye: A Candidate For Modifier Gene Therapy
11/17/2023
Ocugen's Chairman, CEO and Co-founder, Shankar Musunuri ,Ph.D., MBA, provides an update on OCU400 and other ongoing trials, why the eye is a good target for gene therapy, the outlook for retinal gene therapy, and more.
-
How To Migrate Active Studies To A New EDC
11/16/2023
Gain access to the results and lessons learned from a project involving the modernization of an electronic data capture system and mid-study data migrations.
-
2023 Technology Adoption Trends And Plateaus
11/15/2023
About 85% of industry leaders and managers have had some exposure to AI. Delve into the state of AI adoption experienced throughout 2023 and where the industry is headed concerning digital tool usage.
-
Zero Disruptions: Migrating 14 Mid-Study Clinical Trials In 16 Months
11/15/2023
Uncover how Imperial College London was able to effectively transfer 14 ongoing studies, encompassing over 1,700 patients and 150,000+ forms, onto a new EDC platform within 16 months.
-
Proven Process For Managing Clinical Trial Changes, Data Migrations
11/15/2023
Explore how the Imperial College London was able to complete a successful migration of 14 ongoing studies, involving over 1,700 patients and 150,000+ forms, within a 16-month timeframe.
-
3 Steps For Cell & Gene Therapy Medical Affairs Teams To Provide Strategic Value
11/15/2023
Historically, medical affairs has been seen as more of a resource, as the group that answers complex scientific questions. However, medical affairs teams at cell and gene therapy companies must be more strategic.
-
CGT Trials — The Synergy Of CRO And Specialty Logistics Collaboration
11/15/2023
Learn how the right CRO partner is crucial to support the uniquely complex logistical needs of CGTs while prioritizing the working conditions of investigators and the comfort of trial participants.
-
Opportunities To Accelerate Allogeneic Cell Therapy
11/10/2023
Learn more about the potential of allogeneic cell therapies to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.
-
Outsourcing Vendor Red Flag #3: Inaccurate Or Low Bids
11/8/2023
A bad feeling in your gut is a firm starting point, but strategies exist to substantiate a bid’s value based on more than the “sniff test.”